Saphnelo Pen Approval Expands Lupus Treatment Access

AstraZeneca has received approval from the U.S. Food and Drug Administration for a new self-administered version of its lupus treatment, Saphnelo, marking a significant step forward in patient convenience and accessibility. The newly approved Saphnelo Pen allows once-weekly subcutaneous (under-the-skin) administration for adults with systemic lupus erythematosus (SLE), in addition to standard therapy.

The approval is supported by findings from the Phase III TULIP-SC clinical trial, which demonstrated that patients receiving subcutaneous Saphnelo experienced a statistically significant and clinically meaningful reduction in disease activity compared to those receiving a placebo. The study focused on individuals with moderate to severe SLE already undergoing standard treatment. Full results from the trial were published in Arthritis & Rheumatology in January 2026, reinforcing confidence in the therapy’s effectiveness.

Importantly, the safety profile of the subcutaneous formulation was consistent with the previously established profile of Saphnelo delivered via intravenous infusion. This consistency provides reassurance for clinicians and patients transitioning to the more convenient autoinjector format.

Experts in the field have welcomed the development. Dr. Susan Manzi, a principal investigator of the TULIP-SC trial, highlighted that the new self-injection option could make treatment more accessible for a broader group of patients. She emphasized that anifrolumab has already demonstrated its ability to reduce disease activity and lower the risk of long-term organ damage in lupus patients.

Patient advocacy groups have also praised the approval. Louise Vetter, CEO of the Lupus Foundation of America, described the new option as a meaningful advancement, giving patients greater flexibility in how and where they receive treatment.

Systemic lupus erythematosus is a chronic autoimmune disease that disproportionately affects women, particularly those from Asian, Black, and Hispanic populations. It remains a leading cause of death among young women in the United States. While corticosteroids are commonly used to manage symptoms, they are associated with significant side effects and do not address the underlying disease mechanisms.

The introduction of the Saphnelo Pen aligns with evolving treatment guidelines that emphasize achieving remission or low disease activity while minimizing steroid use. With more than 40,000 patients already treated globally, Saphnelo continues to play a growing role in lupus management. The subcutaneous version is already approved in the European Union and Japan and is under review in additional countries.